Construction of PANoptosis signature: Novel target discovery for prostate cancer immunotherapy.

Mol Ther Nucleic Acids · 2023 · PMC10400972 · PMID 37547288

Europe PMC DOI

hedged sentence

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

did not reach statistical significancep = 0.076so close (0.05 < p ≤ 0.1)

A similar trend was found for other clinical features (seminal vesicle invasion, pathologic Gleason score, age, and baseline prostate-specific antigen [PSA]), although these differences did not reach statistical significance (p = 0.076, 0.076, 0.153, and 0.265, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.